Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 3, 2007, Pages 431-437

  Larsen, Roy H ^a   Borrebaek, Jorgen ^b   Dahle, Jostein ^a,c   Melhus, Katrine B ^a   Krogh, Cecilie ^a   Valan, Miriam H ^b   Bruland, Øyvind S ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b Algeta AS   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alpha emitting 227Th; Radioimmunoconjugates

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTIBODY CONJUGATE; CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOIMMUNOCONJUGATE; RITUXIMAB; THORIUM; THORIUM 227; TRASTUZUMAB; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ANTIGEN; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; MONOCLONAL ANTIBODY; SINGLE HETEROCYCLIC RINGS;

ALPHA RADIATION; ANTIGEN BINDING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG STABILITY; HALF LIFE TIME; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE DECAY; SERUM; ARTICLE; BLOOD; IMMUNOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS; CELL LINE, TUMOR; DRUG STABILITY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; INDICATORS AND REAGENTS; THORIUM;

EID: 34447525352     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.321     Document Type: Conference Paper

References (16)

1. Allen BJ, Raja C, Rizvi S, et al. Targeted alpha therapy for cancer. Phys Med Biol 2004;49:3703.
2. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med 1999;40:1197.
3. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med 2005; 46(Suppl. 1):199S.
4. 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120.
5. Tolmachev V, Carlsson J, Lundqvist H. A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy - availability of suitable radionuclides. Acta Oncol 2004;43:264.
6. 227 Th source. Radiochim Acta 2001;89:661.
7. 212Bi. Radiochim Acta 2003;91:109.
8. Henriksen G, Bruland OS, Larsen RH. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents. Anticancer Res 2004;24: 101.
9. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 2002;57:841.
10. 211At-rituximab against non-Hodgkin's lymphoma cells. Br J Cancer 2000;83:1375.
11. Lindmo T, Bunn PA, Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Meth Enzymol 1986;121:678.
12. 227Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl Med Biol 2006;33:271.
13. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451.
14. 223Ra: Adjuvant or alternative to conventional modalities? Clin Cancer Res 2006; 12(Suppl. 20);6250S.
15. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 2002;57:841.
16. 223Ra injected intravenously into mice: Histology, clinical chemistry, and hematology. In Vivo 2006;20:325.